ZymoGenetics Presents Positive Results From RECOTHROM(TM) Thrombin, Topical (Recombinant) Spray Study In Burn Patients
May 15th 2008Drug InformationDermatology
ZymoGenetics, Inc. (NASDAQ:ZGEN), presented results at the American Burn Association annual meeting from a clinical trial with RECOTHROM? Thrombin, topical (Recombinant) administered by spray device to burn wound excision sites. The study evaluated the safety and immunogenicity of RECOTHROM for patients undergoing skin grafting for burns.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
